MS Integrated Center
Welcome,         Profile    Billing    Logout  
 1 Trial 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
McCravey, Brandon
NCT05531526: Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)

Recruiting
3
1150
Europe, US, RoW
AR1001, Placebo
AriBio Co., Ltd.
Alzheimer Disease
12/25
12/27
NCT05399368: An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis

Terminated
2
229
Canada, US
RPT193, Placebo
RAPT Therapeutics, Inc.
Atopic Dermatitis
05/24
05/24
ETNA-MS, NCT06256731: Device Validation Study

Recruiting
N/A
60
US
Eye-Tracking
Innodem Neurosciences, Syneos Health
Multiple Sclerosis
06/24
06/24

Download Options